Children Brain Tumors and the Promise of Precision Medicine
A landmark study from investigators at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center suggests that precision medicine could fundamentally change how children brain tumors are diagnosed and treated. By matching therapies to the specific genetic profile of individual tumors, researchers believe outcomes for pediatric patients can be meaningfully improved.
Despite significant progress in childhood cancer survival over the past three decades, brain tumors have remained one of the most difficult frontiers. Brain tumors account for approximately 25 percent of all cancer related deaths in children, and many current treatment approaches carry a risk of long term cognitive or physical difficulties. The need for more precise, targeted interventions has never been more urgent.
Largest Genetic Study of Pediatric Brain Tumors to Date
In what researchers describe as the largest clinical study to date examining genetic abnormalities in children brain tumors, scientists analyzed more than 200 tumor samples representing all major subtypes of the disease. The findings were published in the journal Neuro-Oncology.
Two complementary testing methods were used. OncoPanel technology sequences specific sections of DNA for irregularities across 300 cancer related genes. OncoCopy examines how many copies of particular genes are missing or overrepresented within tumor cells. Sixty samples were tested with both methods, allowing researchers to evaluate whether a combined approach offered greater diagnostic power.
The results were striking. Among samples tested with OncoPanel, 56 percent carried genetic abnormalities considered clinically relevant, meaning they could influence a patient’s diagnosis or be targeted by drugs already approved or currently under evaluation in clinical trials. Many of these drugs are able to cross the blood brain barrier, a major challenge in treating neurological cancers.
Key Findings From the Research
Among the specific discoveries, researchers identified alterations in the BRAF gene, one of the most commonly mutated genes found in children brain tumors and a target for several drugs currently in development. The two-pronged testing approach proved especially valuable for medulloblastomas, a type of brain tumor accounting for nearly one fifth of all pediatric brain cancer cases. When both tests were used together, clinically relevant abnormalities were detected in 89 percent of medulloblastoma samples.
Co-lead author Pratiti Bandopadhayay of Dana-Farber/Boston Children’s and Harvard Medical School noted that advances in pediatric brain cancer have historically lagged behind other childhood cancers. These findings represent a meaningful step forward.
Why Genomic Profiling Changes the Treatment Equation
The World Health Organization has already moved toward classifying brain tumors by their genetic alterations rather than by broad tumor type, a shift that reflects the growing consensus around precision medicine. Targeted therapies are most effective when matched to the specific abnormalities present in a patient’s tumor cells rather than applied broadly across a disease category.
Study co-senior author Susan Chi of Dana-Farber/Boston Children’s stated that precision medicine for children brain tumors can now be considered a clinical reality, not just a research aspiration.
For families seeking to understand pediatric brain tumor diagnoses and treatment options, the Mayo Clinic offers a comprehensive and accessible overview.
This reclassification has practical consequences for how clinical trials are designed and how patients are enrolled. When tumor subtypes are defined genetically rather than anatomically, trial eligibility criteria become more precise, enrollment becomes more meaningful, and the likelihood of detecting a true treatment effect increases. For children brain tumors specifically, where patient populations are smaller and disease heterogeneity is high, this level of precision is not just beneficial. It is essential.
The Role of Clinical Trials in Pediatric Oncology
Translating genomic discoveries into effective treatments depends on a robust clinical trial infrastructure. Studies evaluating targeted therapies for pediatric brain tumors require sites with the expertise and resources to conduct complex oncology research safely and efficiently.
FOMAT supports oncology clinical research across a national network of investigator sites, contributing to the development of next generation treatments for cancer. To learn about active oncology studies, visit our patient active studies page. For more research insights, explore the FOMAT blogs and updates.